ArticlePDF Available

The impact of Intraoperative Radiotherapy on breast cancer early detection: An Observational Review

Authors:
  • Imam Abdulrahman Bin Faisal university
  • Imam Abdulrahman Bin Faisal University, Dammam, KSA

Abstract and Figures

Aim: The lack of structured breast cancer awareness programs (BCAP) in developing countries coupled by the scarcity of radiation oncology centers limit the available surgical options. The aim of this study is to Probe the use Intraoperative radiotherapy (IORT) treatment as a stem to initiate positive impact on early disease detection and propagate breast conserving surgery (BCS). Materials and Methods: This observational review was undertaken at King Fahd hospital of the university, AL Khobar, Eastern province of Saudi Arabia between 2012- 2016. All patients diagnosed with breast cancer were reviewed. Strict recruitment criteria were adopted for patients to receive IORT. Selected candidates where only those who were eligible and consented to undergo BCS and IORT. Special emphasis was placed on demographic data, tumor size at the initial presentation, post Neo-adjuvant chemotherapy response, post–pathology cavity size and applicator size used. Results: The total number of patients diagnosed with breast cancer were 330 out of which 69 (20%) patient were eligible for IORT. Age ranged from31-75years with the Median age 50 years. Applicator sizes used ranged from 2.0-5.0. Tumor size ranged between 0.6-4.0 centimeters. 1 (1%) was post pathology case with excision performed two weeks prior to presentation. 0-1 in 8(11%), 1.1-2 in 22(31%), 2.1-3 in 24(34%), and 3.1- 4.0 in 15 (21%) patients. 7(10%) patients received Neo-adjuvant chemotherapy with positive response and were included. The applicator sizes available ranged between 1.5-5.0 centimeters. Applicator sizes were size 2.0 in 2 (3%), size 2.5 in 10 (14%), size 3.0 in 18(26%), size 3.5 in 16 (23%), size 4.0 in 10 (14%), size 4.5 in 6 cases (9%) and size 5.0 in 7 cases (10%). Smaller applicator sizes 2.0-3.5 centimeter in diameter were used in 46 (66%) of cases suggesting that smaller lesions are currently been diagnosed. Conclusion: The introduction of Intraoperative radiotherapy (IORT) intended as boost therapy is a break through treatment of early breast cancer. While developing countries remain disadvantaged by the lack of adequate radiotherapy centers to cover its population needs, IORT can offer an alternative solution for a selected subset of women with early breast cancer as an exclusive or boost therapy. Its positive impact on the early detection is well illustrated in this observational study. In addition, its use supported the promotion of BCS in early breast cancer thus, it braced a positive impact on early detection strategies.
Content may be subject to copyright.
International Journal of Cancer Research & erapy
Volume 2 | Issue 2 | 1 of 3
Int J Cancer Res er, 2017
Intraoperative Radiotherapy promoting early Breast Cancer Detection: An observational
Review
Research Article
Maha Abdel Hadi*, Lina Abu Arida, Amal Khalifa and Hiyam Al Haddad
Abstract
Aim: The lack of structured breast cancer awareness programs (BCAP) in developing countries coupled by the
scarcity of radiation oncology centers limit the available surgical options. The aim of this study is to Probe the use
Intraoperative radiotherapy (IORT) treatment as a stem to initiate positive impact on early disease detection and
propagate breast conserving surgery (BCS).
Materials and Methods: This observational review was undertaken at King Fahd hospital of the university, AL
Khobar, Eastern province of Saudi Arabia between 2012- 2016. All patients diagnosed with breast cancer were
reviewed. Strict recruitment criteria were adopted for patients to receive IORT. Selected candidates where only
those who were eligible and consented to undergo BCS and IORT. Special emphasis was placed on demographic
data, tumor size at the initial presentation, post Neo-adjuvant chemotherapy response, post–pathology cavity size
and applicator size used.
Results: The total number of patients diagnosed with breast cancer were 330 out of which 69 (20%) patient were
eligible for IORT. Age ranged from31-75years with the Median age 50 years. Applicator sizes used ranged from
2.0-5.0. Tumor size ranged between 0.6-4.0 centimeters. 1 (1%) was post pathology case with excision performed
two weeks prior to presentation. 0-1 in 8(11%), 1.1-2 in 22(31%), 2.1-3 in 24(34%), and 3.1- 4.0 in 15 (21%)
patients. 7(10%) patients received Neo-adjuvant chemotherapy with positive response and were included. The
applicator sizes available ranged between 1.5-5.0 centimeters. Applicator sizes were size 2.0 in 2 (3%), size 2.5
in 10 (14%), size 3.0 in 18(26%), size 3.5 in 16 (23%), size 4.0 in 10 (14%), size 4.5 in 6 cases (9%) and size 5.0 in
7 cases (10%). Smaller applicator sizes 2.0-3.5 centimeter in diameter were used in 46 (66%) of cases suggesting
that smaller lesions are currently been diagnosed.
Conclusion: The introduction of Intraoperative radiotherapy (IORT) intended as boost therapy is a break through
treatment of early breast cancer. While developing countries remain disadvantaged by the lack of adequate
radiotherapy centers to cover its population needs, IORT can offer an alternative solution for a selected subset of
women with early breast cancer as an exclusive or boost therapy. Its positive impact on the early detection is well
illustrated in this observational study. In addition, its use supported the promotion of BCS in early breast cancer
thus, it braced a positive impact on early detection strategies.
Breast Division, Department of Surgery, Imam Abdulrahman
Alfaisal University Kingdom of Saudi Arabia.
*Corresponding author
Maha Abdel Hadi, Professor/Consultant General & Breast surgeon,
King Fahd hospital of the University, P.O.Box 40293 Al-Khobar
31952, Kingdom of Saudi Arabia, E-mail: mhadi@uod.edu.sa
Submitted: 11 Feb 2017; Accepted: 04 Mar 2017; Published: 15 Sep 2017
Keywords: IORT, Intrabeam, Applicators, Early detection.
Introduction
The fast pace of urbanization in many developing countries
coupled with the imposed changes in life style has resulted in many
alterations in disease patterns. Breast cancer has shown increasing
incidence over the last decades with young age and advanced
disease at the initial presentations [1]. The unpopular Breast Cancer
Awareness programs (BCAP) are focused on didactic educational
lectures with repetitive information. These programs usually dish
out basic knowledge on breast cancer, early detection methods,
and risk factors, however; they generally fail to fully disseminate
information or disclose treatment options [2]. Radiotherapy as
an integral treatment modality in cancer therapy that dictates
its demand. In developing countries and countries with limited
resources these facilities are scarce. They are expensive to establish,
upgrade, and maintain. Stringent plans are needed to estimate the
disease burden to be able to appreciate the cost that may be incurred
by advanced disease [3]. The increase prevalence of breast cancer
in our communities in recent years coupled by cultural stigma and
the limited surgical options of liberal adoption of mastectomies
alienate women from presenting with early disease [4]. In culturally
ISSN: 2476-2377
Volume 2 | Issue 2 | 2 of 3Int J Cancer Res er, 2017
driven communities introducing IORT as boost or exclusive therapy
has nally caught women’s attention. IORT information circulated
through health education programs initiated interest in promoting
breast conserving surgery BCS for early breast cancer.
Materials and Methods
This observational review was undertaken at King Fahd hospital
of the university, AL Khobar, Eastern province of Saudi Arabia
between 2012- 2016. All patients diagnosed with breast cancer
were reviewed. Strict recruitment criteria were adopted for patients
to receive IORT. Selected candidates where only those who
were eligible and consented to undergo BCS and IORT. Special
emphasis was placed on demographic data, tumor size at the initial
presentation. Those with post Neo-adjuvant chemotherapy treatment
and post pathology excision were included. Emphasis was placed
on the cavity size and applicator size used. The applicator sizes
available ranged between 1.5-5.0 centimeters. Wide local excision
with 1-2cm gross margin was adopted in all surgical procedures.
Cavity size is measured and the corresponding applicator size was
chosen. Intraoperative ultrasound was used to conrm the contact of
the target tissue with the applicator. ZIESS INTRABEAM PRS 500
with XRS4 delivering uniformly 20 Gy. to the target tissue.
Results
The total number of patients diagnosed with breast cancer were 330
out of which 69 (20%) patients fullled the strict criteria and were
eligible for IORT. Age ranged from 31-75years with the Median age
50 years. 1 (1%) was post pathology case with excision performed
two weeks prior to presentation. Tumor size reported uniformly by
ultrasound was between 0.6-4.0 centimeters 0-1 in 8(11%), 1.1-2
in 22(31%), 2.1-3 in 24(34%), and 3.1- 4.0 in 15 (21%) patients.
Figure I 7(10%) patients received Neo-adjuvant chemotherapy with
positive response and were included.
Applicator sizes available ranged from 1.5-5.0 centimeter in diameter.
(Figure II) (a,b) Applicator used were size 2.0 in 2 (3%), size 2.5
in 10 (14%), size 3.0 in 18(26%), size 3.5 in 16 (23%), size 4.0 in
10 (14%), size 4.5 in 6 cases (9%) and size 5.0 in 7cases (10%). To
our surprise smaller applicator sizes 2.0-3.5 centimeter in diameter
accounted for 46 (66%) of cases conrming that smaller lesions are
currently been diagnosed. (Figure III) (a,b).
Figure I: Applicators and the Radiation source.
Figure II (a,b): Tumor Size.
Figure III (a,b): Applicator Sizes used.
Discussion
Breast cancer continues to be ranked rst among females worldwide
[5]. It is estimated annual number of cases diagnosed globally with
breast cancer exceeds 1 million and this number is expected to
increase to 1.5 million by the end of the decade because of the major
increase in the number of diagnosed cases in countries with limited
resources [6]. Due to the suboptimal early detection strategies in
developing countries the average tumor size at the time of the initial
presentation is reported as more than 4 centimeters in diameter [7].
Therefore, it is understandable that mastectomy is still advocated
as the rst treatment option by many surgeons and oncologists in
developing countries. The cultural inuence of body image stigma
inicted by the liberal adoption of mastectomies further distant
women from seeking early treatment, hence delayed presentations.
Wide local excision is infrequent, it is practiced cautiously with
major reservations.
While radiotherapy remains an integral adjuvant component in
the treatment of segmental breast resections, yet, the scarcity
of the radiotherapy centers in many developing countries limits
the surgical options offered. Concerns over the global increase
of cancer burden have been voiced by the International Atomic
Energy Agency (IAEA). As the cancer burden increase, the long
term high cost incurred by the treatment of advanced disease and
palliative care reciprocally increase. The least prepared developing
countries take the brunt and the consequences. As the economy
dictates, the number of Radiation Oncology centers worldwide is
scarce and mainly clustered in developed countries [8].
Emerging alarming reports indicate that 57% of cancer cases
occur in low and middle income countries with 50% - 90% of
underprivileged patients requiring radiotherapy are deprived
from access to radiation facilities [9]. The late presentation of
the young women in the reproductive age is both disturbing and
disruptive. Partial treatment contributes to advanced disease and
high mortality for a potentially treatable cases [10].
Tumor size No. of Patients
0-1 8
1.1-2 22
2.1-3 24
3.1-4 15
Applicator size No. of Patients
1.5 0
2.0 2
2.5 10
3.0 18
3.5 16
4.0 10
4.5 6
5.0 7
Volume 2 | Issue 2 | 3 of 3
Int J Cancer Res er, 2017
Extensive efforts have been probed in an attempt to improve
breast cancer management options in developing countries thereby
encouraging women to present early. Sporadic and individual efforts
are commendable yet, they function in a limited scale that do not
signicantly contribute to reality.
The introduction of the modern modality of IORT as targeted
treatment for early breast cancer appears as a breakthrough. It
expected to provide a practical, convenient and efcient method of
treatment both as an exclusive or boost therapy suitable for healthcare
facilities in countries with limited resources. The encouraging results
from this observational study of IORT have prompted women who
would normally shy away with breast masses, resist disclosure and
refuse treatment to present early.
Despite the lack of structured awareness programs in our communities
in this encouraging study the tumors size at the initial presentation
ranged between impalpable masses of 0.6-4 centimeters in largest
diameter. Women were more willing to receive neo-adjuvant
chemotherapy in order to be able to undergo BCS. The applicator
sizes used were smaller in 46 (66%) of cases than the predicted
sizes for treatment. Further, the easy handling of IORT equipment in
the conventional operating rooms shattered all known barriers and
concerns to radiation exposure and safety.
IORT is an efcient, convenient, cost effective, sparing or shortening
the patients the long sessions of external beam radiation while
providing equally effective outcomes [11,12].
Conclusion
While developing countries remain by the lack of adequate
radiotherapy centers to cover its population needs, IORT can offer
an alternative solution for a selected subset of women with early
breast cancer as an exclusive or boost therapy. Its positive impact
on the early detection is well illustrated in this observational study.
References
1. http://who.int/cancer/detection/breastcancer
2. Abdel hadi M, Ratrout H, Al Wadaani H (2015) Rethinking:
Ideal Screening Age for Breast Cancer in Developing
Countries. The journal of breast health 11: 110-114.
3. Goksel F, Koc O, Ozgul N, GultekinM, Abacioglu M, et al.
(2014) Radiation Oncology Facilities in Turkey: Current
Status and Future Perspectives. Asian Pacic J Cancer Prev
12: 2157-2162.
4. Al-Rikabi A, Husain S (2012) increasing prevelance of breast
cancer among Saudi patients attending a tertiary referral
hospital: Retrospective epidemiology study. croat med j 53:
239-243.
5. Abdel Hadi MS (2000) Breast cancer awareness among health
professionals. Saudi Medical Journal 20: 135-136
6. Love R, Love S, Laudico A (2004) Breast cancer from a public
health perspective. Breast Journal 2: 136-140.
7. Al Diab A, Qureshi S, Al Saleh K, Al Qahtani F, Aleem A, et
al. (2013) Review on Breast Cancer in the Kingdom of Saudi
Arabia. Middle-East J Sci Res 14: 532-543.
8. https://www.iaea.org
9. Zubizarreta EH, Fidarova E, Healy B, Rosenblatt E (2015)
Need for radiotherapy in low and middle income countries-
the silent crisis continues. ClinOncol (R CollRadiol) 27 the
silent crisis continues. ClinOncol (R CollRadiol) 27: 107-114.
10. Rodin D, Knaul FM, Lui TY, Gospodarowicz M (2016)
Radiotherapy for breast cancer: The predictable consequences
of an unmet need. Breast 29: 120-122.
11. Vaidya J, Joseph D, Tobias J, Bulsara M, Wenz F, et al.
(2010) Targeted intraoperative radiotherapy versus whole
breast radiotherapy for breast cancer (TARGIT-A trial): an
international, prospective, randomised, non-inferiority phase
3 trial. The Lancet 376: 91-102.
12. Holmes DR, Baum M, Joseph D (2007) The TARGIT
trial: targeted intraoperative radiation therapy versus
conventional postoperative whole-breast radiotherapy after
breastconserving surgery for the management of early-stage
invasive breast cancer (a trial update).Am J Surg 194: 507-
510.
Copyright: ©2017 Maha Abdel Hadi, et al. is is an open-access article
distributed under the terms of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Objective: The aim is to identify the ideal screening age for women in developing countries and to determine the suitable method for early detection of breast cancer based on age and readiness of the community. Materials and methods: A 30-year retrospective review (from 1984 to 2014) was undertaken at King Fahd Hospital of the University, Al-Khobar, Saudi Arabia. Medical records of those diagnosed with breast cancer from the outpatient department and hospital admission records were reviewed, focusing mainly on demographic data, age, and time at presentation. Radiological and histopathological records were also reviewed for confirmation of diagnosis. Age-based statistical review was undertaken of the female population within the hospital catchment area. Results: The total number of patients was 1.832, accounting for 0.8 % affected patients when plotted against the 235,339 females within the catchment area. Considering the standard screening age of 40 years, patients were divided into two groups: group I included those below the age of 40 years at the time of diagnosis, accounting for 641patients (35%), and group II included those above the age of 40 years, accounting for 1191 patients (65%). Group I patients were mostly reassured in primary healthcare centers, diagnostic modalities were used with reservation, relying solely on ultrasonography 276 (43%); whereas in group II patients, mammography was used liberally, which aided in the diagnosis in all 1191 (100%). Conclusion: Despite the undisputable notion that breast cancer has higher predilection for women above the age of 40 years, there is a substantial subset of affected younger women in developing countries, which contradicts this concept. However, the scarcity of structured sessions in developing countries dictates Western-based early detection strategies, but the validity of such programs is culture-governed. Rigorously tailored screening programs directed towards individual communities are mandatory. Reducing the screening age by a decade in developing countries may increase the capture of early breast cancer and improve the outcomes.
Article
Full-text available
Breast Cancer (BC) is considered the most implacable malignancy and the leading cause of mortality in the Kingdom of Saudi Arabia (KSA). The literature on different aspects of BC is rich in contributions from developed and Western countries. Nevertheless, despite substantial individual efforts, the views of experts from KSA lack a collective portrayal. Hence, an attempt has been made to gather together the information in the form of an overview which includes some facets of BC. The views of experts from Saudi Arabia on these aspects of BC in the Kingdom included an amalgamation of a variety of articles published during last more than thirty years from different research and teaching institutions. The task was met up with peer reviewed english language articles cited in Pub Med, Pub Med Central, Science Direct, Up-to-date, Med Line, Comprehensive data bases, Cochrane library and the internet (Google, Yahoo). The study provides impetus on further analysis of the association between epidemiology, knowledge of BC and practice of breast self-examination (BSE), etiological factors, metastases and rate of survival. Further studies are warranted to enrich the information for planning of screening, management and preventive strategies of BC in KSA, which may indirectly benefit worldwide health care.
Article
Full-text available
About 57% of the total number of cancer cases occur in low and middle income countries. Radiotherapy is one of the main components of cancer treatment and requires substantial initial investment in infrastructure and training. Many departments continue to have basic facilities and to use simple techniques, while modern technologies have only been installed in big cities in upper-middle income countries. More than 50% of cancer patients requiring radiotherapy in low and middle income countries lack access to treatment. The situation is dramatic in low income countries, where the proportion is higher than 90%. The overall number of additional teletherapy units needed corresponds to about twice the installed capacity in Europe. The figures for different income level groups clearly show the correlation between gross national income per capita and the availability of services. The range of radiotherapy needs currently covered varies from 0% and 3–4% in low income countries in Latin America and Africa up to 59–79% in upper-middle income countries in Europe and Central Asia. The number of additional radiation oncologists, medical physicist, dosimetrists and radiation therapists (RTTs) required to operate additional radiotherapy departments needed is 43 200 professionals. Training and education programmes are not available in every developing country and in many cases the only option is sending trainees abroad, which is not a cost-effective solution. The implementation of adequate local training should be the following step after establishing the first radiotherapy facility in any country. Joint efforts should be made to establish at least one radiotherapy facility in countries where they do not exist, in order to create radiotherapy communities that could be the base for future expansion.
Article
Full-text available
To determine the pattern of breast diseases among Saudi patients who underwent breast biopsy, with special emphasis on breast carcinoma. A retrospective review was made of all breast biopsy reports of a mass or lump from male and female patients seen between January 2001 and December 2010 at the King Khalid University Hospital, Riyadh, Saudi Arabia. Of 1035 breast tissues reviewed, 939 specimens (90.7%) were from female patients. There were 690 benign (65.8%) and 345 (34.2%) malignant cases. In women, 603 (64.2%) specimens were benign and 336 (35.8%) were malignant. In men, 87 specimens (90.6%) were benign and 9 (9.4%) were malignant. All malignant cases from male patients belonged to invasive ductal carcinoma and the majority of malignant cases from female patients belonged to invasive/infiltrating ductal carcinoma. The proportion of malignancy was 18% in patients younger than 40 years and 63.2% in patients older than 60 years. The mean age of onset for malignancy was 48.6 years. The annual percentage incidence of malignant breast cancer steadily increased by 4.8%, from an annual rate of 23.5% in 2000 to 47.2% in 2007. Among Saudi patients, there is a significant increase in the incidence of breast cancer, which occurs at an earlier age than in western countries. Continued vigilance, mammographic screening, and patient education are needed to establish early diagnosis and perform optimal treatment.
Article
Full-text available
An analysis of the current radiotherapy status in Turkey was conducted to establish a comprehensive baseline. Turkey's future demand analysis in view of international benchmarks was conducted. Moreover, the ministerial plans are shared to present an example for making a comprehensive planning in developing countries. The data from all radiotherapy centers in Turkey was collected through a survey and cross-checked with primary research and government data. Survey covered the status of radiotherapy centers in terms of major equipment and personnel. Data regarding manpower currently working is obtained from relevant academic centers and occupational associations. The latest ministerial registry data demonstrated 150,000 new cancer cases each year with 400,000 patients living with cancer in Turkey. Around 100,000 patients are estimated to need radiotherapy each year--a figure expected to reach around 170,000 by 2023. The current numbers for radiotherapy centers, megavoltage equipment, radiation oncologists, medical physicists and radiotherapy technicians are 90, 186, 446, 130 and 600 respectively. By 2023, Turkey will need around 680 radiation oncologists, 624 medical physicists, 2,650 radiotherapy technicians and 379 megavoltage machines. Turkey faces a slight oversupply of radiation oncologists in contrast to undersupply in megavoltage machines and other personnel. Careful planning is required to allocate limited resources. The purchase of the equipment and employment policies should be structured as part of national cancer control program.
Article
Full-text available
The prevalence of breast cancer in recent years has prompted women to seek medical advice randomly with minimal breast symptoms but only a small number of women are aware of the proper methods of conducting breast self-examination (BSE) or the importance of radiological screening for breast cancer. In the Middle East the incidence of breast cancer is rising and affecting a younger population compared to the West. Breast cancer awareness programs (BCAP) are meant to help in the prevention and early detection of breast cancer. In the Arab world there are very few such programs. In an attempt to develop a structured BCAP in our community and to trigger wide-scale programs 300 women from the medical field were interviewed to be recruited as future health education providers. (excerpt)
Article
Radiotherapy has had a transformative impact on the treatment of breast cancer, but is unavailable to the majority of breast cancer patients in low- and middle-income countries. In these settings, where many women present with advanced disease at an age when they are often the primary caregiver for their families, the lack of access to radiotherapy is particularly devastating. Until recently, this disparity has been largely neglected in the medical literature and it had been difficult to convince governments, industry, and policymakers of the importance of investing in radiotherapy, as well as broader cancer control strategies, in low-resource settings. The Lancet Radiotherapy Commission report published in 2015 challenged many assumptions about the affordability of radiotherapy treatment. Data from the Commission is presented here to support radiotherapy investment for breast cancer and discuss how the morbidity and premature mortality among adult women caused by breast cancer has a huge detrimental effect on both the health sector and the economy.
Article
After breast-conserving surgery, 90% of local recurrences occur within the index quadrant despite the presence of multicentric cancers elsewhere in the breast. Thus, restriction of radiation therapy to the tumour bed during surgery might be adequate for selected patients. We compared targeted intraoperative radiotherapy with the conventional policy of whole breast external beam radiotherapy. Having safely piloted the new technique of single-dose targeted intraoperative radiotherapy with Intrabeam, we launched the TARGIT-A trial on March 24, 2000. In this prospective, randomised, non-inferiority trial, women aged 45 years or older with invasive ductal breast carcinoma undergoing breast-conserving surgery were enrolled from 28 centres in nine countries. Patients were randomly assigned in a 1:1 ratio to receive targeted intraoperative radiotherapy or whole breast external beam radiotherapy, with blocks stratified by centre and by timing of delivery of targeted intraoperative radiotherapy. Neither patients nor investigators or their teams were masked to treatment assignment. Postoperative discovery of predefined factors (eg, lobular carcinoma) could trigger addition of external beam radiotherapy to targeted intraoperative radiotherapy (in an expected 15% of patients). The primary outcome was local recurrence in the conserved breast. The predefined non-inferiority margin was an absolute difference of 2.5% in the primary endpoint. All randomised patients were included in the intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, number NCT00983684. 1113 patients were randomly allocated to targeted intraoperative radiotherapy and 1119 were allocated to external beam radiotherapy. Of 996 patients who received the allocated treatment in the targeted intraoperative radiotherapy group, 854 (86%) received targeted intraoperative radiotherapy only and 142 (14%) received targeted intraoperative radiotherapy plus external beam radiotherapy. 1025 (92%) patients in the external beam radiotherapy group received the allocated treatment. At 4 years, there were six local recurrences in the intraoperative radiotherapy group and five in the external beam radiotherapy group. The Kaplan-Meier estimate of local recurrence in the conserved breast at 4 years was 1.20% (95% CI 0.53-2.71) in the targeted intraoperative radiotherapy and 0.95% (0.39-2.31) in the external beam radiotherapy group (difference between groups 0.25%, -1.04 to 1.54; p=0.41). The frequency of any complications and major toxicity was similar in the two groups (for major toxicity, targeted intraoperative radiotherapy, 37 [3.3%] of 1113 vs external beam radiotherapy, 44 [3.9%] of 1119; p=0.44). Radiotherapy toxicity (Radiation Therapy Oncology Group grade 3) was lower in the targeted intraoperative radiotherapy group (six patients [0.5%]) than in the external beam radiotherapy group (23 patients [2.1%]; p=0.002). For selected patients with early breast cancer, a single dose of radiotherapy delivered at the time of surgery by use of targeted intraoperative radiotherapy should be considered as an alternative to external beam radiotherapy delivered over several weeks. University College London Hospitals (UCLH)/UCL Comprehensive Biomedical Research Centre, UCLH Charities, National Institute for Health Research Health Technology Assessment programme, Ninewells Cancer Campaign, National Health and Medical Research Council, and German Federal Ministry of Education and Research (BMBF).
Article
The principal objective of the targeted intraoperative radiation therapy trial was to determine whether single-fraction intraoperative radiotherapy (IORT) targeted to the tumor bed provides equivalent local control compared with whole-breast irradiation in patients with early-stage invasive breast cancer. Patients were randomized equally to IORT versus whole breast irradiation. Patients randomized to IORT received tumor bed irradiation prescribed at 20 Gy to the surgical margins using soft x-rays (50 kV) delivered with the Intrabeam Photon Radiosurgery System (Zeiss Inc, Oberkochen, Germany). Patients randomized to whole-breast irradiation received radiotherapy postoperatively. Prior wide local excision was allowed. Patients randomized to IORT after initial breast-conserving surgery received IORT at a second operation. A total of 779 patients were accrued at 16 institutions internationally. Five hundred sixty patients were randomized before initial breast-conserving surgery. One hundred eighty-three patients were randomized after initial breast-conserving surgery. The median follow-up time was 359 days. Targeted IORT allowed the entire dose of radiotherapy to be administered in a single fraction at the time of breast-conserving surgery, thus avoiding the need for repeated radiotherapy treatments or placement of indwelling radiotherapy devices.
Article
By 2010, the majority of approximately 1.5 million annual new cases of breast cancer will be diagnosed in women in countries with limited resources. Public health approaches to medical problems emphasize the importance of practical, limited toxicity and very inexpensive interventions. While clinical trials in Western countries are testing the concept of breast cancer prevention, they are not defining useful public health approaches. Early detection of breast cancer using mammography, while effective, is a high-technology, expensive approach. Adjuvant systemic and radiation therapies are increasingly expensive; careful consideration of efficacy and cost-efficacy data appear warranted. Public health perspectives thus suggest that many current "standard" approaches to breast cancer in Western countries cannot help the majority of women in the world.